PMID: 7437241Sep 1, 1980Paper

Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment

British Journal of Clinical Pharmacology
A JohnstonN A Hamer


1 The pharmacokinetics of disopyramide were studied after the oral administration of a 300 mg dose to 11 patients with stable chronic renal impairment (creatinine clearance 2-53 ml min-1). 2 Absorption half-life and volume of distribution were similar to those seen in normal subjects. 3 Mean plasma elimination half-life in these patients was 12.7 h, which is substantially greater than that reported for normal subjects. Elimination half-life tended to increase as creatinine clearance fell, and renal clearance of disopyramide correlated significantly (r=0.814; P < 0.001) with creatinine clearance. 4 From these results, we have calculated that patients with renal impairment should be started on a dose of disopyramide 1.5 mg kg-1 thrice daily and the regimen subsequently altered according to plasma concentrations of the drug. However, further studies are needed to define the handling of the metabolites of disopyramide.


Aug 1, 1978·The Journal of Pharmacy and Pharmacology·K F Rhodes, J F Waterfall
Jun 1, 1979·Clinical Pharmacology and Therapeutics·G S StokesE P MacCarthy
Jun 1, 1976·British Journal of Clinical Pharmacology·G H DraffanC T Dollery
Aug 1, 1977·British Heart Journal·D W Barritt, A J Marshall
Oct 18, 1975·British Medical Journal·J C PetrieJ A Lewis
Aug 1, 1973·The Journal of Pharmacy and Pharmacology·D H Variava, P Turner
Dec 1, 1973·European Journal of Clinical Pharmacology·P J LewisC T Dollery
May 1, 1972·Clinical Pharmacology and Therapeutics·R B RoydsJ D Lockhart

❮ Previous
Next ❯


Jan 1, 1983·European Journal of Clinical Pharmacology·M CanalA Dufour
Jan 1, 1986·European Journal of Clinical Pharmacology·J BondeJ P Kampmann
Jan 1, 1983·European Journal of Drug Metabolism and Pharmacokinetics·B FrancoisM Lussignol
Jan 1, 1983·Pharmacology & Therapeutics·D M Roden, R L Woosley
Nov 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M BennettI Singer
Jan 1, 1989·Fundamental & Clinical Pharmacology·P CacoubC Jacobs
Apr 1, 1983·British Journal of Clinical Pharmacology·B M DavidN S Stenhouse
Mar 1, 1982·Journal of Clinical and Hospital Pharmacy·S M BrysonB Whiting
Apr 1, 1985·Journal of Clinical Pharmacology·M CanalA Baglin
Jan 15, 1988·The American Journal of Cardiology·R L Woosley, C Funck-Brentano
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·A KarimD L Azarnoff

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.